BioLight
BOLTRamat Gan, Israel· Est.
Israel's sole publicly listed ophthalmology‑focused investment platform, BioLight builds a diversified portfolio of innovative eye‑care technologies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Israel's sole publicly listed ophthalmology‑focused investment platform, BioLight builds a diversified portfolio of innovative eye‑care technologies.
Ophthalmology
Technology Platform
Convergent ophthalmology technologies integrating nanostructure drug delivery, AI diagnostics, and advanced medical devices to address unmet eye‑disease needs.
Opportunities
Aging demographics and rising screen‑time‑related eye disorders create strong demand for digital diagnostics, sustained‑release drug delivery, and AI‑enabled retinal screening.
Risk Factors
Regulatory approvals, technology integration across diverse portfolio companies, and competition from larger ophthalmic incumbents could delay commercialization.
Competitive Landscape
BioLight competes with global ophthalmic leaders such as Alcon, Novartis, and Bausch & Lomb, but differentiates through its focused investment model and emphasis on convergent engineering‑driven eye‑care solutions.